Nico Therapeutics Inc. has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer’s disease and nonalcoholic fatty liver disease (metabolic dysfunction-associated ...

Roche has made a second acquisition in the area of NLRP3 inhibitors for inflammatory ... Last year, Novartis bought US biotech IFM Tre – a subsidiary of IFM Therapeutics – in a deal worth ...

Global biotechnology company NodThera is developing a new class of potent and selective small-molecule NLRP3 inhibitors for ... “The current therapeutic targets for treating chronic inflammation ...

Novartis, meanwhile, bought US biotech IFM Tre – a subsidiary of ... reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate ...

they obtained their NLRP3 inhibitor product candidate (DFV890), which is in Phase II clinical trials for the treatment of osteoarthritis, through the acquisition of IFM Therapeutics in 2019.

Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of ...

Nomination of NLRP3 inhibitor BGE-102 as a development candidate, with initial Ph1 clinical data anticipated by end of 2025 Expansion of discovery efforts based on insights from BioAge’s platform, ...

("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product ... proprietary class of NLRP3 inhibitors, which have distinctive structural and biological ...

NEW YORK--(BUSINESS WIRE)--Olatec Therapeutics, Inc., a leader in the developing class of selective NLRP3 inhibitors, today announced that long-time collaborator and advisor, Prof. Dr. Marc Donath ...